GAM Holding AG Cuts Position in Omnicell, Inc. (NASDAQ:OMCL)

GAM Holding AG lessened its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 36.9% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 51,972 shares of the company’s stock after selling 30,371 shares during the quarter. GAM Holding AG’s holdings in Omnicell were worth $2,266,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in OMCL. Nisa Investment Advisors LLC grew its holdings in Omnicell by 248.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares in the last quarter. GAMMA Investing LLC grew its holdings in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after buying an additional 553 shares in the last quarter. EntryPoint Capital LLC grew its holdings in Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after buying an additional 1,345 shares in the last quarter. CWM LLC grew its holdings in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after buying an additional 1,236 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of Omnicell in the 2nd quarter worth approximately $104,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

Shares of OMCL stock opened at $41.10 on Wednesday. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $45.84. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. The firm has a market capitalization of $1.89 billion, a P/E ratio of -89.35, a P/E/G ratio of 45.31 and a beta of 0.83. The stock has a 50 day moving average price of $43.21 and a 200 day moving average price of $34.52.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The business had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. Omnicell’s revenue was down 7.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.29 EPS. As a group, sell-side analysts predict that Omnicell, Inc. will post 0.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on OMCL shares. Wells Fargo & Company lifted their target price on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a report on Saturday. JPMorgan Chase & Co. lifted their target price on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Benchmark reiterated a “buy” rating and issued a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Finally, Bank of America lifted their target price on Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $41.33.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.